Allopurinol in Acute Gout

This study has been withdrawn prior to enrollment.

(because of a lack of funding)

Sponsor:

Information provided by (Responsible Party):

Artur de Brum-Fernandes, Universitaire de Sherbrooke

ClinicalTrials.gov Identifier:

NCT01775098

First received: January 21, 2013

Last updated: NA

Last verified: January 2013

History: No changes posted

Tracking Information
First Received Date ^ICMJE	January 21, 2013
Last Updated Date	January 21, 2013
Start Date ^ICMJE	Not Provided
Estimated Primary Completion Date	April 2013 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: January 21, 2013)	Duration of the gout crises [ Time Frame: First 7 days after visit ] [ Designated as safety issue: No ] Presence of inflammatory signs
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Allopurinol in Acute Gout
Official Title ^ICMJE	Allopurinol in Acute Gout
Brief Summary	The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Not Provided
Study Design ^ICMJE	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment
Condition ^ICMJE	Gout
Intervention ^ICMJE	Drug: allopurinol
Study Arm (s)	Experimental: Allopurinol treatment with allopurinol Intervention: Drug: allopurinol Placebo Comparator: placebo placebo comparator
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Withdrawn
Enrollment ^ICMJE	0
Completion Date	Not Provided
Estimated Primary Completion Date	April 2013 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: More than 18 years old Able to sign informed consent Indication of long-term treatment with allopurinol Acute gout crisis Exclusion Criteria: Les than 18 years-old Unable to consent Contra-indication to allopurinol
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01775098
Other Study ID Numbers ^ICMJE	Allopurinol in acute gout
Has Data Monitoring Committee	Yes
Responsible Party	Artur de Brum-Fernandes, Universitaire de Sherbrooke
Study Sponsor ^ICMJE	Universitaire de Sherbrooke
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Universitaire de Sherbrooke
Verification Date	January 2013
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top